Format

Send to

Choose Destination
Ann N Y Acad Sci. 2012 Aug;1263:29-40. doi: 10.1111/j.1749-6632.2012.06674.x. Epub 2012 Jul 25.

The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.

Author information

1
Amgen Inc., Thousand Oaks, California, USA. cgoessl@amgen.com

Abstract

Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL), an essential cytokine for the formation, function, and survival of osteoclasts. The role of excessive RANKL as a contributor to conditions characterized by bone loss or bone destruction has been well studied. With its novel mechanism of action, denosumab offers a significant advance in the treatment of postmenopausal osteoporosis; bone loss associated with hormone ablation therapy in women with breast cancer and men with prostate cancer; and the prevention of skeletal-related events in patients with bone metastases from solid tumors by offering clinical benefit to these patients in need.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center